EnClear Therapies Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
18
EnClear Therapies General Information
Description
Developer of device-based therapies designed to treat neurological diseases. The company's neurology-focused device-based systems remove toxic proteins as therapies and provide closed-loop delivery and monitoring of cerebrospinal fluids (CSF), enabling doctors to halt the progression of the disease and extend the lives of patients with amyotrophic lateral sclerosis (ALS) and progressive supranuclear palsy (PSP).
Contact Information
Website
www.encleartherapies.comCorporate Office
- 65 Parker Street
- Suite 3A
- Newburyport, MA 01950
- United States
Corporate Office
- 65 Parker Street
- Suite 3A
- Newburyport, MA 01950
- United States
EnClear Therapies Timeline
EnClear Therapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 03-Sep-2024 | Completed | Clinical Trials - General | |||
| 5. Grant | 03-Sep-2024 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series 3) | 01-Mar-2024 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 18-Feb-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A2) | 26-Mar-2019 | $2M | $2M | Completed | Product Development | |
| 1. Accelerator/Incubator | Completed | Product Development |
EnClear Therapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed-1 | ||||||||
| Series A-2 | 124,003 | $0.000100 | 6% | $17.28 | $17.28 | 1x | $6 | 3.35% |
| Series A-1 | 210,539 | $0.000100 | 6% | $45 | $45 | 1x | $14.9 | 5.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
EnClear Therapies Comparisons
Industry
Financing
Details
EnClear Therapies Competitors (2)
One of EnClear Therapies’s 2 competitors is QurAlis, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| QurAlis | Venture Capital-Backed | Cambridge, MA | ||||
| OncoDNA | Venture Capital-Backed | Gosselies, Belgium |
EnClear Therapies Patents
EnClear Therapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250360269-A1 | Method and apparatus for determining patency for an intrathecal access site | Pending | 22-May-2024 | ||
| WO-2025245323-A1 | Method and apparatus for determining patency for an intrathecal access site | Pending | 22-May-2024 | ||
| EP-4673192-A2 | Csf therapeutic delivery system | Pending | 28-Feb-2023 | ||
| US-20240285854-A1 | Csf therapeutic delivery system | Pending | 28-Feb-2023 | ||
| WO-2024182544-A2 | Csf therapeutic delivery system | Inactive | 28-Feb-2023 | A61M5/16877 |
EnClear Therapies Signals
EnClear Therapies Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Founders Fund | Venture Capital | Minority | ||
| National Cancer Institute | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| The Brain Tumor Investment Fund | Not-For-Profit Venture Capital | Minority | ||
| The Sontag Foundation | Limited Partner | Minority |
EnClear Therapies FAQs
-
When was EnClear Therapies founded?
EnClear Therapies was founded in 2018.
-
Where is EnClear Therapies headquartered?
EnClear Therapies is headquartered in Newburyport, MA.
-
What is the size of EnClear Therapies?
EnClear Therapies has 9 total employees.
-
What industry is EnClear Therapies in?
EnClear Therapies’s primary industry is Therapeutic Devices.
-
Is EnClear Therapies a private or public company?
EnClear Therapies is a Private company.
-
What is EnClear Therapies’s current revenue?
The current revenue for EnClear Therapies is .
-
How much funding has EnClear Therapies raised over time?
EnClear Therapies has raised $12.7M.
-
Who are EnClear Therapies’s investors?
Founders Fund, National Cancer Institute, National Institutes of Neurological Disorders and Stroke, The Brain Tumor Investment Fund, and The Sontag Foundation are 5 of 18 investors who have invested in EnClear Therapies.
-
Who are EnClear Therapies’s competitors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process